Alger Spectra Fund stated the following regarding Eli Lilly and Company (NYSE ... Jardiance (diabetes and obesity), Taltz (psoriasis), Emgality (migraines), and Verzenio (breast cancer).

Eli Lilly is to buy the private biotech Disarm ... has also made some progress with its already-marketed neurology drug Emgality (galcanezumab), after NICE okayed NHS funding in final draft ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

Ajovy was approved later in 2018 but its sales didn’t warrant a mention in Teva’s third-quarter update, while third-to-market Emgality (galcanezumab) from Eli Lilly – the only drug to have ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.